BERKELEY, Calif., February 9, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the appointment of Jason O’Byrne as Chief Financial Officer (CFO). An accomplished executive with more than 20 years of experience within high-growth biotechnology environments, Mr. O’Byrne most recently served as Senior Vice President of Finance at Audentes Therapeutics.
In the News
Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products
“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”
AbbVie and Caribou Team Up On Next-Gen Off-the-Shelf CAR-T Therapies
“AbbVie and Caribou are partnering to develop next-generation off-the-shelf CAR-T therapies for oncology indications. The collaboration centres around Caribou’s chRDNA technology to overcome challenges facing existing off-the-shelf CAR-T therapies.”